Cailin Conner

DocwireNews

A common comorbidity in heart failure (HF) patients is gout. Moreover, gout is associated with significantly higher rates of morbidity, mortality, and health care costs. Diuretics, often prescribed to patients with cardiac-related health problems, can lead to hyperuricemia (elevated uric acid levels in the blood) and increase the risk of gout flares. Gout in HF patients has been estimated to range from 16% to 40%. Colchicine, used to treat acute gout flares, has also recently demonstrated broader cardiovascular outcomes benefit in high&#8208;risk patients; however, the literature of its impact in patients with acutely decompensated HF is somewhat sparce. A retrospective study published in <a href="https://onlinelibrary.wiley.com/doi/10.1002/clc.23830" target="_blank" rel="noopener">Clinical Cardiology</a> sought to rectify this and investigated clinical outcomes in patients treated for an acute HF exacerbation who received colchicine for acute gout flares.The authors of the study examined adult patients with an acute HF exacerbation who received colchicine to treat an acute gout flare versus a control group without gout flare. Data and covariates were collected from patients&rsquo; medical records. The primary outcome measurement was in-hospital all-cause mortality, and secondary outcomes included hospital length of stay (LOS), 30-day readmission, and time to death. Additionally, researchers compared primary and secondary outcome measurements between patients with a prior history of gout and patients with an initial diagnosis of gout.After exclusions, 237 patients were included in the colchicine group and 810 patients were included in the control group. Patients in the colchicine group were more likely to be younger, male, consume alcohol, and have a history of gout compared with the control group. Overall, the in-hospital all-cause mortality rate was 5.5%. When comparing cohorts, patients in the colchicine cohort had rates lower in-hospital all-cause mortality (2.1% vs 6.5%). The 30-day readmission rates were comparable between cohorts, and the mean LOS was significantly higher in the colchicine group (9.93 days) compared with the control group (7.96 days). No significant differences were observed in any primary or secondary outcome between patients with a new gout diagnosis compared with patients with a history of gout.&ldquo;The underlying mechanistic pathways that could explain the potential benefits of colchicine in the HF population are largely unknown but may be multifactorial,&rdquo; the authors said. While the authors indicated the need for large multicenter retrospective and prospective randomized studies are still needed, they added, &ldquo;if indeed our findings are validated, then consideration could be made for designing clinical trials that incorporate anti-inflammatory agents such as colchicine targeting this vulnerable phase of worsening HF.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Clinical Outcomes of Colchicine Use for Gout in HF Patients

Heart Failure

A common comorbidity in heart failure (HF) patients is gout. Moreover, gout is associated with significantly higher rates of morbidity, mortality, and health care costs. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe